AR078522A1 - Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis - Google Patents

Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis

Info

Publication number
AR078522A1
AR078522A1 ARP100103604A ARP100103604A AR078522A1 AR 078522 A1 AR078522 A1 AR 078522A1 AR P100103604 A ARP100103604 A AR P100103604A AR P100103604 A ARP100103604 A AR P100103604A AR 078522 A1 AR078522 A1 AR 078522A1
Authority
AR
Argentina
Prior art keywords
group
compound
alkyl
synthesis
prepare
Prior art date
Application number
ARP100103604A
Other languages
English (en)
Spanish (es)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43719548&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR078522(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR078522A1 publication Critical patent/AR078522A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20Spiro-condensed ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP100103604A 2009-10-15 2010-10-04 Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis AR078522A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25183909P 2009-10-15 2009-10-15
US30333410P 2010-02-11 2010-02-11

Publications (1)

Publication Number Publication Date
AR078522A1 true AR078522A1 (es) 2011-11-16

Family

ID=43719548

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100103604A AR078522A1 (es) 2009-10-15 2010-10-04 Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis

Country Status (25)

Country Link
US (1) US8383642B2 (https=)
EP (1) EP2488500A1 (https=)
JP (1) JP2013508279A (https=)
KR (1) KR20120051777A (https=)
CN (1) CN102574807A (https=)
AR (1) AR078522A1 (https=)
AU (1) AU2010307094A1 (https=)
BR (1) BR112012008889A2 (https=)
CA (1) CA2777775A1 (https=)
CL (1) CL2012000921A1 (https=)
CO (1) CO6531458A2 (https=)
CR (1) CR20120177A (https=)
DO (1) DOP2012000105A (https=)
EA (1) EA201270560A1 (https=)
EC (1) ECSP12011799A (https=)
IL (1) IL218344A0 (https=)
MA (1) MA33662B1 (https=)
MX (1) MX2012004420A (https=)
NZ (1) NZ598972A (https=)
PE (1) PE20121437A1 (https=)
PH (1) PH12012500705A1 (https=)
TN (1) TN2012000152A1 (https=)
TW (1) TW201124415A (https=)
WO (1) WO2011046851A1 (https=)
ZA (1) ZA201202560B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2411393T1 (sl) 2009-03-23 2014-03-31 Glenmark Pharmaceuticals S.A. Kondenzirani pirimidin-dionski derivati kot TRPA 1 modulatorji
EP2411395B1 (en) 2009-03-23 2013-05-29 Glenmark Pharmaceuticals S.A. Furopyrimidinedione derivatives as trpa1 modulators
AR078948A1 (es) * 2009-11-30 2011-12-14 Lilly Co Eli Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes
CN104710381A (zh) 2009-12-25 2015-06-17 持田制药株式会社 新的3-羟基-5-芳基异噻唑衍生物
JP5809157B2 (ja) 2010-10-08 2015-11-10 持田製薬株式会社 環状アミド誘導体
CN103517637B (zh) 2011-03-11 2015-12-02 洲际大品牌有限责任公司 形成多层糖食的系统和方法
RU2013152631A (ru) 2011-04-27 2015-06-10 Мотида Фармасьютикал Ко., Лтд. Новое 3-гидроксиизотиазол-1-окидное производное
JPWO2012147516A1 (ja) 2011-04-28 2014-07-28 持田製薬株式会社 環状アミド誘導体
TWI537262B (zh) * 2011-08-17 2016-06-11 美國禮來大藥廠 供治療糖尿病使用之新穎1,2,3,4-四氫喹啉衍生物
WO2013139341A1 (en) * 2012-03-20 2013-09-26 Syddansk Universitet Gpr120 receptor modulators
WO2013185766A1 (en) * 2012-06-15 2013-12-19 Syddansk Universitet Gpr120 receptor modulators
RS55363B1 (sr) 2012-11-16 2017-03-31 Bristol Myers Squibb Co Dihidropirazolni gpr40 modulatori
KR101569522B1 (ko) * 2013-04-18 2015-11-17 현대약품 주식회사 신규한 3-(4-(벤질옥시)페닐)헥스-4-이노익 산 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물
EP3068788A1 (en) * 2013-11-14 2016-09-21 Cadila Healthcare Limited Novel heterocyclic compounds
US20150351889A1 (en) 2014-06-05 2015-12-10 Vivex Biomedical Inc. Dynamic Biometric Mesh
MX387086B (es) 2014-10-17 2025-03-19 Hyundai Pharm Co Ltd Preparacion compuesta, que contiene derivado novedoso de acido 3-(4-(benciloxi)fenil)hex-4-inoico y otro ingrediente activo, para prevenir o tratar enfermedades metabolicas
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
CN109666027A (zh) * 2017-10-17 2019-04-23 中国科学院上海药物研究所 一类酰胺结构的gpr40激动剂化合物及其用途
US11964938B2 (en) 2018-01-08 2024-04-23 Celon Pharma S.A. 3-phenyl-4-hexynoic acid derivatives as GPR40 agonists
CR20200347A (es) 2018-02-13 2020-09-23 Gilead Sciences Inc Inhibidores pd-1/pd-l1
TWI712412B (zh) 2018-04-19 2020-12-11 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
SG11202012425QA (en) 2018-07-13 2021-01-28 Gilead Sciences Inc Pd-1/pd-l1 inhibitors
WO2020086556A1 (en) 2018-10-24 2020-04-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
KR20220150270A (ko) 2019-10-07 2022-11-10 칼리오페, 인크. Gpr119 효능제
TW202140440A (zh) 2020-02-28 2021-11-01 美商克力歐普股份有限公司 Gpr40激動劑
WO2021236617A1 (en) 2020-05-19 2021-11-25 Kallyope, Inc. Ampk activators
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4489354B2 (ja) 2001-04-18 2010-06-23 ユーロ−セルティーク エス.エイ. スピロインデンおよびスピロインダン化合物類
CN1768041A (zh) 2003-04-04 2006-05-03 麦克公司 作为黑皮质素-4受体激动剂的酰化螺哌啶衍生物
US7504506B2 (en) 2003-11-04 2009-03-17 Elixir Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US7834013B2 (en) 2003-11-19 2010-11-16 Glaxosmithkline Llc Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to GPR40
CA2558585C (en) 2004-02-27 2010-10-12 Amgen Inc. Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
US7517910B2 (en) 2004-03-30 2009-04-14 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
EP1924546A1 (en) 2005-09-14 2008-05-28 Amgen, Inc Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
CA2662242C (en) 2006-09-07 2012-06-12 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
BRPI0818687A2 (pt) 2007-10-26 2017-05-02 Japan Tobacco Inc composto espiro, o sal deste farmaceuticamente aceitavél ou o solvato deste, composição farmacêutica, medicamento agonista de gpr40, agente promotor da secreção de insulina ou um agente hipoglicêmico, uso do composto espíro, o sal deste farmaceuticamente aceitavél ou o solvato deste, e, métodos para a ativação de gpr40, para promover secreção de insulina ou diminuir o nível de glicose sanguínea, e para tratar ou prevenir uma doença.
JP2011504499A (ja) 2007-11-21 2011-02-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ トリプターゼ阻害剤として使用するためのスピロピペリジン
AR078948A1 (es) 2009-11-30 2011-12-14 Lilly Co Eli Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes

Also Published As

Publication number Publication date
MA33662B1 (fr) 2012-10-01
CA2777775A1 (en) 2011-04-21
CL2012000921A1 (es) 2012-09-14
DOP2012000105A (es) 2013-01-31
WO2011046851A1 (en) 2011-04-21
KR20120051777A (ko) 2012-05-22
EP2488500A1 (en) 2012-08-22
IL218344A0 (en) 2012-04-30
US8383642B2 (en) 2013-02-26
AU2010307094A1 (en) 2012-04-19
NZ598972A (en) 2013-06-28
MX2012004420A (es) 2012-05-08
PH12012500705A1 (en) 2012-10-29
ZA201202560B (en) 2013-09-25
PE20121437A1 (es) 2012-10-26
BR112012008889A2 (pt) 2019-09-24
EA201270560A1 (ru) 2012-09-28
TW201124415A (en) 2011-07-16
CR20120177A (es) 2012-06-06
ECSP12011799A (es) 2012-07-31
US20110092531A1 (en) 2011-04-21
CN102574807A (zh) 2012-07-11
JP2013508279A (ja) 2013-03-07
TN2012000152A1 (en) 2013-12-12
CO6531458A2 (es) 2012-09-28

Similar Documents

Publication Publication Date Title
AR078522A1 (es) Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
AR071187A1 (es) Compuesto de arilmetil-tiazinamina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento de la enfermedad de alzheimer
AR065806A1 (es) Derivados de quinolina, procesos para su preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de la artritis reumatoidea.
EA200701176A1 (ru) Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
UY32062A (es) Inhibidores de beta-secretasa
AR086254A1 (es) Derivados de imidazol utiles para el tratamiento de artritis
AR077277A1 (es) Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
EA201500266A1 (ru) Ингибиторы репликации вирусов гриппа
CU20110216A7 (es) Derivados aminobutíricos sustituidos como inhibidores de neprilisina
MX2015003653A (es) Derivados de amida del acido benzoimidazol-carboxilico como moduladores del receptor apj.
CR20110616A (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
UA109199C2 (uk) Дигідропіридинові сполуки, корисні для лікування від залежності, викликаної агентами, що стимулюють вироблення дофаміну
AR086100A1 (es) Compuestos de cromenona y composiciones farmaceuticas que los contienen
GT200600086A (es) Forma cristalina de gamma-d del clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen
AR077014A1 (es) Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
CL2011003302A1 (es) Compuestos derivados de amida del acido alquil-sulfonico; composicion farmaceutica; uso de los compuestos como moduladores de la disfuncion de glutamato para prevenir o tratar trastornos neurologicos y psiquiatricos como esquizofrenia, enfermedad de alzheimer, trastornos de deficit de atencion/hiperactividad, perdida de audicion, entre otros.
EA201490726A1 (ru) Фармацевтические соединения для применения в терапии инфекции clostridium difficile
MA38260A1 (fr) Nouveaux dérivés de cyclohexyl et quinuclidinyl carbamate ayant une activité d'agoniste adrénergique beta2 et une activité d'antagoniste muscarinique m3
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
MA38854A1 (fr) Dérivés amides utilisés en tant qu'antagonistes des récepteurs de l'acide lysophosphatidique
JO3360B1 (ar) الشكل البلوري الجديد 3 للأغوميلاتين وعملية تحضيره والمكونات الصيدلانية التي تحتويه
AR056369A1 (es) Compuestos derivados de quinazolina y composicion farmaceutica
RU2013136895A (ru) Новое бициклическое соединение или его соль
AR079343A1 (es) Compuesto de acido 2-amino-4-(4h-1,2,4-triazol-3-ilsulfanil)biciclo[3.1.0]hexano-2,6-dicarboxilico, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar un trastorno psiquiatrico

Legal Events

Date Code Title Description
FA Abandonment or withdrawal